Canton Strategic Holdings, Inc. (Nasdaq: CNTN) released its financial results for the third quarter ended September 30, 2026, reporting total revenue of $3.05 million. This figure represents a 104% increase from the second quarter of 2026, where revenue was approximately $1.50 million. The company attributes this growth to its first full quarter of Super Validator and locking-as-a-service operations.
Revenue for the quarter was composed of $1.50 million from network validation revenue and $1.55 million from other revenue, primarily derived from its locking-as-a-service offering. The company reported a net loss of $35.08 million for the quarter, compared to a net loss of $19.25 million in the previous quarter. Despite the net loss, Canton Strategic achieved its first positive quarterly Adjusted EBITDA of $610,414, a significant improvement from the negative Adjusted EBITDA of $(820,449) recorded in Q2 2026.
Operational highlights for the period included an increase in Super Validator weight to 6.5, up from 0.5 at the end of the second quarter. The company also completed the sale of its legacy clinical-stage biotechnology subsidiary, Gravitas Life Sciences, Inc., on July 17, 2026, in exchange for an unsecured promissory note with a principal amount of $3.5 million bearing 15% payment-in-kind interest.
As of September 30, 2026, the company held 3.83 billion units of Canton Coin (CC) with a fair value of $482.15 million. Cash and cash equivalents stood at $26.92 million. The company noted that the remaining approved Super Validator weight of 8.5 is expected to unlock through the first quarter of 2028, subject to the company meeting deliverables and CC holdings requirements.